Search Results

1 - 10 of 12 items :

  • "serum free light chains" x
Clear All
The Importance of Free Light Chains of Immunoglobulins Determination in Serum

References Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem 2005; 51: 805-7. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673-80. Bradwell AR, editor. Serum free light chain analysis, 4th ed. Birmingham: The Binding Site Ltd., 2006: 285. Solomon A. Light chains of human

Open access
Recommendations for Use of Free Light Chain Assay in Monoclonal Gammopathies

References Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673-80. Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem 2005; 51: 805-7. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489

Open access
Evaluation of the prognostic and predictive value of free light chains in patients with chronic lymphocytic leukemia – preliminary results

treatment of chronic lymphocytic leukemia. Contemp Oncol (Pozn) 2015:361–7. Hus I Roliński J Current concepts in diagnosis and treatment of chronic lymphocytic leukemia Contemp Oncol (Pozn) 2015 361 – 7 [8] Vyas N, Hassan A. Recent advances in chronic lymphocytic leukemia. Indian J Cancer 2012;49:137–43. 10.4103/0019-509X.98940 Vyas N Hassan A Recent advances in chronic lymphocytic leukemia Indian J Cancer 2012 49 137 – 43 [9] Charafeddine KM, Jabbour MN, Kadi RH, et al. Extended use of serum free light chain as a biomarker in

Open access
Comparison of the free and total light chain assays in serum and urine samples with immunofixation electrophoresis for detecting monoclonal proteins in patients with monoclonal gammopathy

References 1. Abraham R.S. et al.: Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin. Chem., 48, 655, 2002. 2. Bradwell A.R. et al.: Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin. Chem., 47, 673, 2001. 3. Bradwell A.R.: Serum Free Light Chain Analysis. 6th ed. Bradwell 2010. 4. Bradwell A.R. et al.: Serum test for assessment of patients with Bence Jones myeloma

Open access
Free Light Chains of Immunoglobulin as a Prognostic Factor for Some Plasmaproliferative Diseases

, pathobiology, technology and clinical applications. AACC Press, Washington, USA, 2002; 305-19. Alanakian MA, Abbas A, Delarue R, Arnulf B, Aucouturier P. Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion. Am J Hematology 2004; 75: 246-8. Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem 2005; 51: 805-7. Rajkumar SV, Kyle RA, Thernearu TM, Melton LJ III, Bradwell

Open access
Increased Monoclonal Components: Prevalence in an Italian Population of 44 474 Outpatients Detected by Capillary Electrophoresis/ Povišene monoklonske komponente: prevalencija u skupini 44.474 italijanskih nehospitalizovanih ispitanika detektovana kapilarnom elektroforezom

2010; 24(6): 1121-7. 3. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ III, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106(3): 812-7. 4. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23(2): 215-24. 5. Kyle RA, Therneau TM, Rajkumar

Open access
Recommendations for use of Tumor Markers in Monoclonal Gammopathies

electrophoresis. Electrophoresis 1997; 18 : 1775-80. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47 : 673-80. Drayson MT, Tang LX, Drew R, Mead GP, Carr-Smith HD, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory myeloma. Blood 2001; 97 : 290-2. Katzmann JA, Abraham RS, Dispenzieri A, Lust J

Open access
A Case of Multiple Myeloma Diagnosed by Renal Biopsy

References 1. Akar H, Seldin DC, Magnani B, et al. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid 2005; 12(4): 210-215. 2. Herrara GA(ed). The kidney in plasma cell dyscrasias Contrib Nephrol Basel Karger 2007; 153: 25-43. 3. Herrara GA(ed). The kidney in plasma cell dyscrasias Contrib Nephrol Basel Karger 2007; 153: 5-24. 4. Herrara GA(ed). The kidney in plasma cell dyscrasias Contrib Nephrol Basel Karger 2007; 153: 66-86. 5

Open access
Prognostic Biomarkers in Early-Stage B-CLL Patients

in chronic lymphocytic leukemia since Binet A stages. Haematolica. 2009; 94(6):887-8. 15. Sarris K, Maltezas D, Koulieris E, Bartzis V, Tzenou T, Sachanas S, et al. Prognostic significance of serum free light chains in chronic lymphocytic leukemia. Clin Adv Hematol. Oncol. 2013 Oct 29;ID 359071. 16. Baumann T, Delgado J, Santacruz R, Martínez-Trillos A, Rozman M, Aymerich M, et al. CD49d (lTGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukemia and mutated IGHV status. Br J Haematol. 2016;172(1):48-55.

Open access
Diagnostic approach to light-chain cardiac amyloidosis and its differential diagnosis

immunofixation of serum and urine should be performed to display the presence of monoclonal (M) protein and abnormal serum free light chain (FLC) ratio in AL amyloidosis. Monoclonal IgG protein (35%), IgA protein (10%), IgM protein (5%), and IgD protein (1%), as well as free light chains (49%), can be found in AL amyloidosis patients [ 23 ]. Lambda light chains are present in 70%, kappa type in 25%, and the biclonal type in 5% of patients [ 24 ]. Typically, lambda chains prevail over kappa in the ratio of 3:1, which differs from multiple myeloma, in which this ratio is 2

Open access